AUL
TGTX icon

AlphaGrep UK Ltd’s TG Therapeutics TGTX Stock Holding History

AlphaGrep UK Ltd’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$308K Buy
9,271
+1,833
+25% +$54.6K 0.09% 491
2025
Q4 		$222K Buy
+7,438
New +$243K 0.07% 583

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

AlphaGrep UK Ltd's TGTX Position: Q1 2026 in Review

AlphaGrep UK Ltd increased its TG Therapeutics (TGTX) stake by 25% in Q1 2026, buying an estimated $54.6K and bringing the position to 9,271 shares worth $308K. The position accounts for 0.09% of the portfolio, ranked #491.

AlphaGrep UK Ltd first reported a position in TGTX in Q4 2025 and has held it in 2 quarters since. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • AlphaGrep UK Ltd held 9,271 shares of TG Therapeutics worth $308K as of Q1 2026.
  • AlphaGrep UK Ltd bought 1,833 TG Therapeutics shares in Q1 2026, an estimated $54.6K.
  • TG Therapeutics made up 0.09% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #491 holding.
  • AlphaGrep UK Ltd first reported a position in TG Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.